FSMB moves one step closer to Interstate Medical Licensure Compact

Laura Pedulli | | Health Exec | Precision Medicine

The Federation of State Medical Boards (FSMB) has completed the drafting process for model legislation to establish an Interstate Medical Licensure Compact.

A statement from FSMB, a national nonprofit representing the 70 medical and osteopathic boards, said the compact would help accelerate the process of issuing licenses for physicians who desire to practice in multiple states. It also establishes the location of a patient as the jurisdiction for oversight and patient protections.

“With the drafting process complete, state legislatures and medical boards can now begin to consider the adoption of this model legislation establishing an interstate medical licensure compact,” said Humayun J. Chaudhry, MD, president and CEO of FSMB, in a statement.

Participation in the interstate compact would be voluntary for both states and physicians. It is expected to facilitate licensure portability and telemedicine while expanding access to health care by physicians, particularly in underserved areas of the nation, according to FSMB.

Read the model legislation here.

 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.